Skip to content
beroni logo newberoni logo new
  • About
    • About Beroni
    • Our History
    • Board of Directors
    • Management Team
    • Vision, Mission and Values
  • R&D
  • Core Businesses
    • Cell Therapies
    • Anti-Cancer Drugs
    • Infectious Diseases
    • Infectious Diseases – COVID-19
    • E-commerce
  • Products
    • By Beroni China
    • By Beroni USA
    • By Beroni Biotech
  • Investors
    • Announcements
    • Financial Information
    • Corporate Governance
    • Stock Information
    • Globenewswire Press Releases
    • Medtech Outlook
    • Research Report
    • COVID-19 Vaccines Overview
    • FAQs
  • News
  • Contact
  • English
    • 简体中文
Menu Close

2021 Press Release

Date

Title

28/5/2021

Beroni Group Issues US$2 Million of Convertible Notes to Fund Research and Development Plans

28/5/2021

Beroni Group Signs MoU with tella, Inc to Collaborate in Immunotherapy for Cancer Treatment

27/4/2021

Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export Permit

3/2/2021

Beroni Acquires Majority Interest in PENAO, an Anti-Cancer Drug Development Company

Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) and traded on the OTC markets in the USA with business presence in Australia, China, Japan and the USA. It currently has four core businesses – research and development of new drugs and clinical trial, immune cell therapy including gene detection and diagnosis, immunotherapy for cancer treatment, diagnosis of infectious diseases and e-commerce based on the Internet sales of pharmaceutical, healthcare and cosmetic products.

About

  • About Beroni
  • Our History
  • Board of Directors
  • Management Team
  • Vision, Mission, and Values

Core Businesses

  • Cell Therapy
  • Anti-Cancer Drugs
  • Infectious Diseases
  • E-Commerce

Products

  • By Beroni China
  • By Beroni Japan
  • By Beroni USA

Copyrights© Beroni Group 2019 | All rights reserved |

website by chase e-Design

Close Menu